Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Rhea-AI Summary

Phio Pharmaceuticals (NASDAQ: PHIO) announced on November 7, 2025 that its INTASYL compound PH-762 won the 2025 Immunomodulatory Solution of the Year award from the BioTech Breakthrough Awards program.

The company is a clinical-stage biopharmaceutical developer using its proprietary INTASYL siRNA gene‑silencing platform focused on cancer therapies. Company leadership highlighted PH-762 as an intratumoral immunotherapy intended to enhance cancer treatment efficacy, and the award organization noted PH-762 addresses a medical need for non‑surgical options for cutaneous carcinomas.

King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL^® siRNA gene silencing technology to eliminate cancer. Phio announced today that its INTASYL compound PH-762 is the winner of the 2025 Immunomodulatory Solution of the Year award.

This is the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe.

"I'm honored that our INTASYL PH-762 has been awarded 'Immunomodulatory Solution of the Year' from the BioTech Breakthrough Awards Program," said Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals. "We believe our intratumoral immunotherapy represents a promising approach to enhance cancer treatment efficacy."

Bryan Vaughn, Managing Director, of BioTech Breakthrough stated, "PH-762 specifically fulfills a medical need for a non-surgical treatment option for patients with cutaneous carcinomas."

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The ongoing Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.

For additional information, visit the Company's website, www.phiopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells, the potential for PH-762 to present a viable non-surgical alternative for skin cancer, expectations regarding timing of enrollment, the expectations that we have sufficient capital to complete the treatment phase of our ongoing Phase 1b clinical trial, and statements regarding our clinical strategy, development plans and timelines and other future events.  

 These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.  Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, results from our preclinical and clinical activities, our ability to execute on business strategies, the timing or likelihood of regulatory filings and approvals, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.  

About BioTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Immunology, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughAwards.com

Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.

Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273500

FAQ

What did Phio Pharmaceuticals (PHIO) announce on November 7, 2025?

Phio announced that its INTASYL compound PH-762 won the 2025 Immunomodulatory Solution of the Year award.

What is INTASYL PH-762 and what stage is it in for PHIO (PHIO)?

INTASYL PH-762 is an intratumoral immunotherapy built on Phio's INTASYL siRNA platform; the company is described as clinical-stage.

How did BioTech Breakthrough describe PH-762's clinical need for PHIO (PHIO)?

BioTech Breakthrough said PH-762 fills a medical need for a non-surgical treatment option for patients with cutaneous carcinomas.

Does the award for PH-762 indicate regulatory approval for PHIO (PHIO)?

No; the announcement reports an industry award and does not state any regulatory approval or clearance.

Could the PH-762 award affect PHIO (PHIO) investor perception or visibility?

The award may increase visibility and investor interest, but the announcement does not provide financial metrics or guidance.

Where can investors find more information about PH-762 and Phio (PHIO)?

Investors can review company public disclosures and clinical updates for details; the announcement highlights the award and company statements about PH-762.